Epctu
Ended Awarded Last action
- Contract number
- 75N93023F00001
- Awardee
-
Dynport Vaccine Company LLC UEI LXNEGTYDR755
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,265,501
Award facts
- Contract value 100% obligated
- $2,265,501.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $245,549 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $219,169 | |
| Exercise an Option | $1,517,618 | |
| Original award | $283,165 |
About this award
This is a $2,265,501.00 delivery order contract awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Early Phase Clinical Trial Units (EPCTU) IDIQ contract vehicle. The contract is for cost plus fixed fee services to support early phase clinical trials, with a period of performance through July 15, 2025.
The contract does not have a set-aside designation. Dynport Vaccine Company has previously provided preclinical development, clinical trials, diagnostics, and manufacturing services to NIAID, HHS, and the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. Two subcontractors, Kcas LLC and Altasciences Clinical Kansas Inc., have been identified to provide services under this task order. Altasciences, in particular, has an extensive history of executing advanced clinical pharmacology research contracts for federal agencies, including a $21 million IDIQ with the National Institute on Drug Abuse.
Quick answers
Who was awarded contract 75N93023F00001?
75N93023F00001 was awarded to Dynport Vaccine Company LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 15, 2023.
How much is contract 75N93023F00001 worth?
The government has obligated $2,265,501 on 75N93023F00001.
Is contract 75N93023F00001 an order under another contract?
Yes. 75N93023F00001 is a delivery order under 75N93022D00016, an indefinite delivery contract, on Early Phase Clinical Trial Units (EPCTU).
Was contract 75N93023F00001 competed?
The extent of competition for 75N93023F00001 was full and open competition. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award